Rose Sharon Shabet's Net Worth
$0
Who is Rose Sharon Shabet?
Rose Sharon Shabet does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Amylyx Pharmaceuticals, Inc., Adaptive Biotechnologies Corp, Zentalis Pharmaceuticals, LLC, RayzeBio, Inc., Inhibrx, Inc., Arbutus Biopharma Corp, Myovant Sciences Ltd., Roivant Sciences Ltd., PROCEPT BioRobotics Corp, BridgeBio Pharma, Inc., 4D Molecular Therapeutics, Inc., Ginkgo Bioworks Holdings, Inc., APi Group Corp, FIGS, Inc., Urovant Sciences Ltd., Axovant Sciences Ltd., Rallybio Corp, Frazier Lifesciences Acquisition Corp, STANDARD BIOTOOLS INC., and Inhibrx Biosciences, Inc..
SEC CIK
Rose Sharon Shabet's CIK is 0001711393
Past Insider Trading and Trends
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Adaptive Biotechnologies Corp (ADPT) Snapshot price: $4.21
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -3.23% | -1.00M |
$55.65 | -$55,650,000.00 | 29.99M |
Dec 14
| |||
Form 4
| -7.46% | -2.50M |
$49.52 | -$123,787,500.00 | 30.99M |
Nov 11
| |||
Form 4
| -7.46% | -2.50M |
$49.52 | -$123,787,500.00 | 30.99M |
Nov 11
| |||
Form 4
| -12.79% | -4.91M |
$24.98 | -$122,706,039.29 | 33.49M |
Jan 28
| |||
Form 4
| -12.79% | -4.91M |
$24.98 | -$122,706,039.29 | 33.49M |
Jan 28
| |||
Form 4
| +2,595.20% | 36.98M |
$20.00 |
—
| 38.41M |
Jul 1
| |||
Form 4
| +2,595.20% | 36.98M |
$20.00 |
—
| 38.41M |
Jul 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Urovant Sciences Ltd. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +0.08% | 18.2K |
$8.32 | $151,380.99 | 22.86M |
Scheduled
|
Jun 17 - Jun 19
| ||
Form 4
| +0.08% | 18.2K |
$8.32 | $151,380.99 | 22.86M |
Scheduled
|
Jun 17 - Jun 19
| ||
Form 4
| +0.10% | 22.01K |
$8.06 | $177,300.64 | 22.84M |
Scheduled
|
Jun 12 - Jun 14
| ||
Form 4
| +0.10% | 22.01K |
$8.06 | $177,300.64 | 22.84M |
Scheduled
|
Jun 12 - Jun 14
| ||
Form 4
| +0.09% | 21.34K |
$8.31 | $177,247.38 | 22.82M |
Scheduled
|
Jun 7 - Jun 11
| ||
Form 4
| +0.09% | 21.34K |
$8.31 | $177,247.38 | 22.82M |
Scheduled
|
Jun 7 - Jun 11
| ||
Form 4
| +0.09% | 21.12K |
$7.86 | $165,950.15 | 22.8M |
Scheduled
|
Jun 4 - Jun 6
| ||
Form 4
| +0.09% | 21.12K |
$7.86 | $165,950.15 | 22.8M |
Scheduled
|
Jun 4 - Jun 6
| ||
Form 4
| +0.08% | 17.75K |
$7.83 | $138,946.36 | 22.78M |
Scheduled
|
May 30 - Jun 3
| ||
Form 4
| +0.08% | 17.75K |
$7.83 | $138,946.36 | 22.78M |
Scheduled
|
May 30 - Jun 3
| ||
Form 4
| +0.06% | 14.48K |
$7.63 | $110,461.18 | 22.76M |
Scheduled
|
May 24 - May 29
| ||
Form 4
| +0.06% | 14.48K |
$7.63 | $110,461.18 | 22.76M |
Scheduled
|
May 24 - May 29
| ||
Form 4
| +0.04% | 19.83K |
$5.61 | $87,804.93 | 48.41M |
Scheduled
|
May 21 - May 23
| ||
Form 4
| +0.09% | 19.83K |
$8.22 | $162,918.35 | 22.75M |
Scheduled
|
May 21 - May 23
| ||
Form 4
| +0.07% | 21.61K |
$7.63 | $162,884.29 | 31.35M |
May 16 - May 20
| |||
Form 4
| +0.07% | 21.61K |
$7.63 | $162,884.29 | 31.35M |
May 16 - May 20
| |||
Form 4
| +13.38% | 2.68M |
$14.00 | $37,499,994.00 | 22.7M |
Oct 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Myovant Sciences Ltd. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +6.32% | 2.42M |
$8.25 | $19,999,996.50 | 40.77M |
Jun 4
| |||
Form 4
| +6.32% | 2.42M |
$8.25 | $19,999,996.50 | 40.77M |
Jun 4
| |||
Form 4
| +2.98% | 1.11M |
$20.27 | $22,500,004.05 | 38.34M |
Apr 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Arbutus Biopharma Corp (ABUS) Snapshot price: $4.5488
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Axovant Gene Therapies Ltd. (SIOX) Snapshot price: $0.45
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +6.71% | 6.67M |
$1.50 | $10,000,000.50 | 105.95M |
Mar 18
| |||
Form 4
| +6.71% | 6.67M |
$1.50 | $10,000,000.50 | 105.95M |
Mar 18
| |||
Form 4
| +11.20% | 10M |
$1.00 | $10,000,000.00 | 99.29M |
Dec 18
| |||
Form 4
| +11.20% | 10M |
$1.00 | $10,000,000.00 | 99.29M |
Dec 18
| |||
Form 4
| +19.05% | 14.29M |
$1.75 | $24,999,999.50 | 89.29M |
Jun 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||